Introduction
Biocatalysis, which exploits the ability of enzymes to convert cheap starting materials into higher priced chemical products, offers many new opportunities for the creation of effective and sustainable synthetic routes. For instance, new synthetic pathways using enzymes can start from alternative feedstocks and use mild reaction conditions. These features, together with benefits such as the elimination of costly protection (and de-protection) of innovative sustainable processes of great value to industry. Furthermore, enzymes are a renewable catalyst (produced by fermentation). The exquisite selectivity of enzyme catalysis, in many cases without precedent in conventional chemo-catalysis, gives great precision as a synthetic tool, and this has resulted in the majority of industrial biocatalytic processes to date being implemented in the pharmaceutical sector [1, 2] . High profile examples include the synthesis of Sitagliptin (the active ingredient in Januvia ® ) catalysed by a transaminase [3] and Atorvastatin (the active ingredient in Lipitor ® ) catalysed by a three enzyme mixture of ketoreductase, glucose dehydrogenase and halohydrin dehalogenase [4] .
Nevertheless, as the cost of enzyme production continues to fall, this in turn opens new opportunities. Today, biocatalysis finds a potential role in the synthesis of products where the development drive comes increasingly from lowering operating (and even capital) costs, rather than speed of implementation. During the implementation of many of the existing biocatalytic processes, it was necessary to find solutions to otherwise intractable problems due to the natural properties of enzymes to operate at very low concentrations of reactant (and by implication product) and their ability to deactivate over time. Inventive engineers found solutions for many of these problems using methods such as reactant feeding, enzyme immobilization and in situ product removal. This also fitted well the conventional design paradigm used in the chemical industry, whereby (i) known reaction pathways are identified as potential routes to products, (ii) suitable catalysts are selected, and finally, (iii) reactors and product recovery schemes are designed to match (usually in that order).
However, compared with chemo-catalysts, enzyme-based catalysts harbour an interesting additional feature. The amino acids which constitute and largely define, not only the active site environment, but indeed the rest of these large protein catalysts, also determine the kinetic characteristics of a given enzyme. Hence, by swapping the amino acids, it becomes possible to alter the catalytic properties of the enzyme. The technology to do this effectively was driven largely by the pioneering work of Chen & Arnold [5] and Stemmer [6] in the early 1990s. Interestingly, synthetic chemists [7] recognized, very early in the development of this technology, the potential of protein engineering to direct catalysis toward the synthesis of new molecules, and create new reactions, all with the particular ability to tune selectivity, when required. Using these approaches, spectacular progress has been made and, in the last decade alone, myriad reactions have been forthcoming, using isolated enzymes individually and increasingly in multienzyme networks and cascades. Indeed, over the last two decades, the field of protein engineering has grown into a scientific discipline in its own right [8] [9] [10] . Today, it is well established that alteration of these amino acids results in changes to enzyme activity (reaction rate), selectivity and stability [11] . By combining library creation with methods for screening, it is possible to select variants with desirable properties, provided an intelligent screen can be defined. An additional requirement is that the screen is high-throughput, because very quickly it becomes clear that the number of variants which need to be screened is very large. Library creation is therefore limited in so far as not all sequence space can be covered, and this has driven the development of more rational approaches (using computer-based methods), guiding engineers to the relevant amino acids to be changed. For some properties such as activity and selectivity, those amino acids in (or around the entrance to) the active site would appear to be most critical. For other properties such as stability, those distal from the active site would appear to have a greater influence. Despite huge advances in our understanding, there are many exceptions to such rules. Numerous scientific reports allude to examples of order-of-magnitude, or more, improvements in enzyme properties, as well as new advances in methodology, screening approaches, high-throughput methods and, more recently, computational developments [12] . Targets are particularly focused on the development of new enzyme function, as well as the tuning of selectivity, but more recently have also included improving enzymes to work effectively under industrial process conditions. An excellent recent review highlights some of the applications with a focus on the pharmaceutical industry [13] .
Interestingly, protein engineering has the potential to be just as powerful a tool for process engineering as has already been demonstrated so successfully for synthetic chemistry. In this brief review, the implications of integrating protein engineering with process design in this way will be discussed, with the objective of further improving the effective implementation of biocatalytic processes.
Enzyme catalysis
Although not all enzymes of potential interest to synthetic or process chemists are commercially available (and at a sufficient scale), the range is growing rapidly and today already it is possible to conceive of artificial cascades of enzymes, driven by the needs of organic chemistry, focused on those reactions which are problematic using conventional chemo-catalysis (e.g. reactions using non-sustainable or hazardous reagents, or those which require molecular protection or directing functional groups). Indeed, a recent seminal article in the field stimulates the idea that whole new areas of chemistry can be explored using so-called biocatalytic retrosynthesis [14] , increasingly limited by imagination alone. For many synthetic chemists, this opens whole new areas of research, which complement existing catalytic methods. The enzymes can be used in different formats, schematically represented in figure 1 .
At the simplest level, the biocatalyst can be a single enzyme, catalysing the introduction, transfer or cleavage of a specific functional group from a reactant molecule (figure 1a). Today, there are very many examples in the academic and industrial scientific literature of such reactions, and a huge variety of products can be made ranging from lower-priced products such as high-fructose corn syrup using glucose isomerase (commercialized for many decades) and FAME (biodiesel) using lipase (commercialized in the last 5 years) [15] to higher priced pharmaceutical APIs, including chiral alcohols using lipases, chiral amines using transaminases and chiral epoxides using epoxide hydrolases [16] . At the next level of complexity, several enzymes are used together, either in the form of a multienzyme cascade or in a cyclic system driving equilibrium towards the desired product or regenerating cofactors (when required) (figure 1b) [17] [18] [19] [20] [21] . This is a more recent development and offers huge potential for combining enzymes in ways that have not previously been applied in nature, while exploiting the relatively similar operating conditions of most enzymes. Recent examples include the synthesis of 1,2-aminoalcohols using, for instance, combinations of transketolase and transaminase or alternatively combinations of lipase and transaminase [22] . At the final level of complexity are those enzymes which are difficult to isolate from cells, or which need cofactors or energy from a metabolizing (although not growing) cell. They can be used as so-called resting cells (sometimes termed microbial biocatalysts), where the cells house the enzyme pathway or network of interest, but without any of the reactant diverted to cell growth, as occurs in fermentation (figure 1c) [23] [24] [25] . For example, Flaviolin was recently synthesized using a pathway in permeabilized Escherichia coli cells [26] , and, likewise, hydroxyabietic acid was also synthesized in permeabilized E. coli cells [27] . The characteristics of these three conversion systems using the different biocatalyst formats are described in more detail in table 1.
Biocatalytic processes
While fermentation processes use the reactant to produce product, they also use the reactant to produce the biocatalyst (microbial cells) which catalyses the production of that product (autocatalysis). Aside from a loss of yield, this also implies that the rate at which such product is produced is therefore linked to the rate at which the cells can grow. It is interesting to note that in conventional aerobic fermentation processes, this places a limit upon the productivity (spacetime yield) of the process at around 2 g l −1 h −1 , and for large volume products this is clearly insufficient. Calculated values based on carbon uptake are usually a little higher [28] , and it seems likely that oxygen transfer limits fermentation productivity [29] . By contrast to fermentation processes, biocatalytic processes use the reactant directly to make the product. Consequently, while they may use a microbial biocatalyst (or an isolated enzyme) to catalyse the reaction, the cell growth and enzyme-catalysed conversion steps are now independent. This has three potential benefits. First, the rate of product formation is no longer dependent on the rate of cell growth, but rather the mass of biocatalyst added. In this way, far higher space-time yields can be achieved (up to 40 g l −1 h −1 or higher, dependent on the specific enzyme activity and any potential mass transfer limitations). Such values are much closer to existing implemented chemical processes. Secondly, the restrictions imposed by the cellular metabolism (such as diversion of cofactor for cell growth) are now lifted. Indeed, where stable, enzymes may be used outside the cell environment as discussed earlier (biocatalyst formats depicted in figure 1a,b) . Finally, the independence of the conversion and biocatalyst growth, mean that providing the biocatalyst is stable enough, it may be recycled and reused, bringing down the contribution of the biocatalyst production to the final product cost. In some cases, this may be essential, if for example the enzyme has been isolated from the cells incurring extra costs [30] . A simple schematic flowsheet of a biocatalytic process is shown in figure 2 , indicating the possibility of recycle of both biocatalyst and unreacted reactant.
Industrial process requirements
Although significant progress has been made in developing and implementing biocatalytic processes in industry in recent years, it remains the case that many potentially interesting biocatalytic processes from an industrial perspective suffer a common problem, which is that the enzymes (and cells containing them) have already been optimized by evolution in nature over several millennia. In principle, using optimized (bio)catalysts would seem ideal until one realizes that the objective function in nature is rather different from that in a process plant [31] . Several challenges can arise from this. For example, some of the most interesting synthetic chemistry from a commercial perspective is based on entirely new reactants, never before seen in nature (non-natural reactants). This is frequently the case, for example in the synthesis of new pharmaceutical intermediates. The implication of this is that a 'wild-type' enzyme may have very little measurable activity on a new reactant, resulting in very low specific reaction rates (g product/g enzyme/h). Likewise in nature, enzymes usually work in an aqueous medium. However, while enzymes and cells thrive in such an environment, the problem is that many of the compounds of greatest interest from a commercial perspective are those based on poorly watersoluble reactants, implying the use of low concentrations of reactant or alternatively formation of a second phase of the reactant (solid or liquid). Finally, in nature, the objective is to be effective and therefore enzymes use low concentrations of reactants (which results in low concentrations of product). Since enzymes have regulation built into their kinetics, inhibition (reversible loss of activity) or toxicity (irreversible loss of activity) by the reactant or product of the enzyme is also seen at relatively low concentrations. Clearly, when attempts are made to translate this into an industry process, the use of low concentrations of reactants (and therefore products) results in very large product recovery equipment and high operational costs. Some examples of process and enzyme improvements which are often necessary to enable scale-up and industrial implementation are given in table 2.
The specific improvement necessary will vary from case to case, and solutions also involve a variety of different strategies. The improvements themselves are largely self-explanatory in the context of the preceding arguments, but shifting thermodynamics is surprisingly useful in processes, where an alternative route might have been selected to a conventional process. Enzyme reactions creating chiral centres, for example, can only be run in one direction, and this is sometimes thermodynamically unfavourable. In such cases, the shifting of thermodynamics can be of great importance [32] . 
Current approaches to process design
Today, the design of biocatalytic processes follows the same principles as other catalytic processes where, following catalyst selection, characterization determines the features which lead to reactor selection and ultimately the product recovery steps. Inventive process solutions have often been required to manage the conditions demanded by the enzyme. For example, a common feature of nearly all biocatalytic processes is the need to increase the concentration of reaction components (reactants and products) when developing and scaling processes from the laboratory to pilot and process plant. This is driven by the need to keep the volume of water to be removed to a minimum, prior to product recovery. One solution, developed by engineers, is to integrate the conversion step with the first product recovery step, using the established process intensification principle of reaction-separation integration. In bioprocesses, this is most commonly termed in situ product recovery (ISPR), although most schemes proposed use a recycle loop (figure 3) so as to isolate the biocatalyst from the recovery operation [33] [34] [35] . Such an approach can give significant process performance improvements of up to one order of magnitude. Likewise, most biological reactions are carried out in an aqueous medium. Despite the fact that water is a benign reagent, this is far from ideal as described earlier, because many compounds of industrial interest (reactants and products) are either poorly water soluble, or inhibitory at low concentrations, or both. Among the strategies to overcome such challenges is reactor compartmentalization, which involves separation of the reactor into two 'compartments'. In one compartment, the reactant is present at a high concentration, and in the other (the reaction medium containing the enzyme) at a low concentration. This can be achieved, for example, by choosing compartments which are different phases and exploiting the difference in affinity of the reactant (and product) for the two phases. During the reaction, the product may also partition back to the high concentration compartment. Such an approach has commonly been used in aqueous-organic two liquid-phase biocatalytic reactions, originally proposed in the 1980s [36] . Although there are some extra considerations required for effective operation (such as ensuring sufficient interphase mass transfer), the system provides excellent opportunities to assist process implementation [37] [38] [39] . Several more recent examples illustrate the power of this approach [40, 41] , although more work is required on solvent selection. Other researchers consider the use of a solid phase to compartmentalize the reactor [42, 43] in order to overcome the use of organic solvents, although here too the selection of the second phase remains challenging.
Designing biocatalysts to match processes
Just as protein engineering has revolutionized the potential for using enzymes as sustainable catalysts in synthetic chemistry, so too it could be argued that it should have a major role in process design, scale-up and implementation. Unlike chemo-catalysis, the use of enzymes also carries the option of protein engineering the enzymes to have a new set of properties. Indeed, the progress made by biotechnologists and molecular biologists working in enzyme expression and protein engineering has reduced the cost contribution of enzymes to many processes, but it is only relatively recently that it has also been used to address improvements to the biocatalyst which can directly improve the process (rather than improving issues such as enzyme reactant scope and selectivity). Although it might be argued that instead of designing reactors, it is the enzyme which is now 'designed', nevertheless this is perhaps too simplistic, because reactants and products of interest to industry come with other challenges such as volatility, low water solubility and unfavourable thermodynamics. The solution to these problems is not (directly) through protein engineering; therefore, alternative solutions must be found from inventive process engineering. Essentially, both process engineering and protein engineering offer complementary solutions to the process design problem. In this way, biological manipulations of the biocatalyst can be seen, from the process design perspective, as a new tool for the process engineer, for example in process intensification. An excellent example to illustrate the point concerns the use of the enzyme ω-transaminase to catalyse the synthesis of optically pure chiral amines from ketones [44, 45] . This is a particularly important reaction for the synthesis of new pharmaceutical intermediates. Here, industrial scientists and engineers working at Merck (Rahway, NJ, USA) and Codexis (Redwood City, CA, USA) in a collaborative effort engineered the enzyme, so that it could work on a previously unseen reactant to synthesize the anti-diabetic compound Sitagliptin. After engineering sufficient enzyme activity (75-fold improvement per mass of enzyme), they intensified the process by increasing the enzyme tolerance to work under the required process conditions (100 g l −1 substrate, pH 8.5 and 45°C) [3] . Subsequently, they immobilized the enzyme to enable recycle and operation for 200 h in organic solvent [46] . Success was directly attributable to the dual approach of protein engineering and process engineering. Both approaches (protein engineering and process engineering) can clearly deliver the necessary targets for process implementation, but the extent to which improvements can be made and the cost/benefit analysis of a given approach will vary from case to case [30] . The integration of protein engineering with process engineering (and design) is therefore a topic that has relevance not only for process engineers charged with the design and eventual implementation of such processes, but also molecular biologists seeking to improve the enzymes (by protein engineering). Today, the two methodologies are too often carried out in very different environments and relatively few reports in the scientific literature have focused on the need to integrate the methodologies [30, 47, 48] , although several industrial examples illustrate well the benefits [4, 13, 49, 50] . In reality though, such a level of integration can open many new opportunities by applying multiple strategies in a synergistic manner [51] .
From the perspective of design, the biocatalytic process has gained an additional degree of freedom-the alteration of the catalyst properties through protein engineering. This also brings the challenge that it is necessary to incorporate this into process design in an effective way. With this in mind, we have recently proposed the use of target-setting, based on process requirements to guide protein engineering, in an analogous way to using the required productivity and economic scenario to guide conventional process design.
Target-setting as a tool to guide protein engineering
It is clear that modifying the biocatalyst can fundamentally alter the possibilities for implementing a commercially viable process. With this in mind, we have recently proposed a modification to the design paradigm such that emphasis is placed on very early-stage process evaluation [52] . The rationale behind this is to assess at an early stage the potential that protein engineering can have on process design. This is necessary because effective protein engineering requires suitable development time. Indeed, whether the process is required for product in the low price sector (e.g. bulk chemicals) or high price sector (e.g. pharmaceuticals), it is equally relevant to evaluate as early as possible what biocatalyst improvements are required. However, evaluation at an early stage also means that it is necessary to describe the process relatively simply and characterize the process performance by simple metrics, rather than detailed costing. Essentially, the process metrics are surrogates for the key economic drivers in the process. Typical metrics for biocatalytic processes include:
(1) Reaction yield (g product/g reactant), which, together with the value difference between the reactant and the product, reflects the value added by the reaction. For lower-priced products, this will be the dominant metric. (2) Volumetric productivity (g product/l reactor/h), which reflects the ultimate size of the process plant required and therefore capital cost. In principle, in a biocatalytic process, this can always be increased, but may eventually be limited by mass transfer limitations or alternatively the specific productivity. (3) Specific productivity (g product/g enzyme/h), together with the required volumetric productivity, this will determine the enzyme concentration (g enzyme/l reactor) required and can become limiting. (4) Product concentration (g product/l reactor), which reflects the downstream processing operating and capital costs. Conventional processes might use an equivalent metric concerning product purity, but the dominance of water in bioprocesses means that concentration steps following biocatalysis are expensive and are therefore a better choice in this case. (5) Enzyme yield (g product/g biocatalyst), which reflects the cost contribution of the biocatalyst to the product. There is little doubt about the importance of this further metric, but its measurement and validation are more complex because the values are dependent on the format of the biocatalyst [53] .
Recently, in the field of fermentation, a similar (although not identical) set of process metrics was proposed and found to correlate well with economic performance [28, [54] [55] [56] , although more as a method of reporting process performance, rather than driving development and process improvement.
The paradigm we propose is to use the metrics as a guide to compare performance at different stages of development and set targets for protein engineering and process engineering in order to attain the ultimate goal of process design (leading to scale-up and implementation) in as effective a way as possible.
Alongside such developments, in the future, more effort will be required in bioreaction engineering [57] and the development of process models to describe biological reactions and processes [58] to assist in the quantitative analysis of alternative enzyme and process improvement strategies. Such quantification becomes essential when the rate laws describing the kinetics should also incorporate the inhibitory effects of substrates and products. These effects are critical in evaluating possibilities for enzyme and process improvement.
Example: improving oxygen transfer by protein engineering
For synthetic and process chemists alike, oxygenases and oxidases are particularly interesting enzymes, used in nature to selectively introduce oxygen into complex molecules. In all such cases, the supply of molecular oxygen, usually from a separate air phase in the reactor (fed via a sparge tube), needs to match the rate of consumption in the liquid phase, where the enzyme catalyses the oxidation [59] . The basic equation, which governs the mass transfer of oxygen in such a system from the gas phase (air) to liquid phase (reaction medium), is given by the following expression:
where K L A is the overall mass transfer coefficient, C O * is the liquid-phase concentration of oxygen in equilibrium with the gas phase and C O is the liquid-phase oxygen concentration in the bulk liquid phase. As explained in a recent publication [60] , the liquid-phase oxygen concentration (C O ) is determined not only by the oxygen transfer rate to the bulk liquid phase (from the gas) (equation (9.1)), but also by the consumption rate of the oxygen by the enzyme-catalysed reaction. This consumption rate is determined by the parameters in the relevant rate law determining the kinetics of the enzyme reaction. The simplest example of such a rate law (with several assumptions) is given by the following expression (the so-called Michaelis-Menten equation):
where V max is the maximum rate of oxygen consumption (by reaction) and K MO is the Michaelis constant on oxygen. When the rate of transfer (equation (8.1)) equals the rate of consumption (equation (8.2)), it is possible to evaluate among other things how effectively the enzyme is used (i.e. how close the enzyme operates to V max ). For example by decreasing the Michaelis constant on oxygen, K MO , it is possible to use the enzyme more effectively for a given value of K L A (figure 4). Interestingly, the literature reports several examples of enzymes with relatively high values of the Michaelis constant of oxygen, K MO , relative to the equilibrium oxygen concentration in solution, C O *. A possible explanation for this is that this was not desirable from an evolutionary perspective, due to competition with other enzyme activities for example, and therefore never evolved. A recent publication sheds significant light on this interesting observation [61] . From a practical perspective, as discussed by Toftgaard Pedersen et al. [60] based on this simple analysis, a new objective for protein engineering to lower K MO values becomes evident. Using the metrics described previously, it is possible to set a target for the required productivity and this, together with a realistic value for K L A at the scale ultimately required, can be used to calculate a target value for K MO . Without the analysis presented here, such as approach would probably not be immediately obvious. In this way, the use of target-setting and problem analysis can help inform the new process design paradigm.
Concluding remarks
New opportunities for implementation of biocatalytic processes will lie in (i) retrofitting existing processes, (ii) replacing existing processes with bioprocesses, (iii) introducing completely new processes for current products that instead rely on new, bio-derived feedstocks, and (iv) introducing new products made by new routes. The relative importance of these different options will be industry dependent. Nevertheless, no matter which route is followed, while today there are many examples of industrial biocatalytic processes producing interesting products, the further implementation of new processes in industry will be dependent on ever-increasing application of systematic process design methods. A range of technologies is available from process engineering methods to enzyme engineering methods. While the complexity of the process design task is greater in most biocatalytic processes due to the extra degree of freedom as a result of using a biological catalyst, it is also necessary to make use of this in order to effect successful implementation. Many new opportunities are possible as a result of integrating the two strategies of protein engineering and process engineering.
Nevertheless, while the true integration of these two methodologies remains a challenging prospect, it should be centre stage for engineers and process scientists interested in the industrial implementation of the many fascinating opportunities enzymes can offer organic chemistry. The extent to which such integration will become routine as a new process design paradigm is probably dependent on the specific industrial sector. For example, those industries which are already using biology are likely to make the integration first. There is little doubt that such improvements, backed by quantitative analysis, pave the way for a new era of cooperation between process engineering, biotechnology and synthetic chemistry, to yield sustainable catalytic processes.
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